Crinetics Pharmaceuticals, Inc.
Develops oral therapeutics for endocrine diseases and endocrine-related tumors.
CRNX | US
Overview
Corporate Details
- ISIN(s):
- US22663K1079
- LEI:
- Country:
- United States of America
- Address:
- 6055 LUSK BLVD., 92121 SAN DIEGO
- Website:
- https://www.crinetics.com/
- Sector:
- Manufacturing
Description
Crinetics Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. The company leverages its expertise in G-protein coupled receptors (GPCRs) to develop orally administered therapies aimed at addressing unmet medical needs. Its lead product candidate is paltusotine, an oral, nonpeptide somatostatin receptor type 2 (SST2) agonist for the treatment of acromegaly and carcinoid syndrome. The company's pipeline also includes atumelnant, an oral ACTH antagonist for conditions of excess cortisol such as congenital adrenal hyperplasia and Cushing's disease. Crinetics aims to build a leading endocrinology company by pioneering treatments that offer patients better disease control and greater convenience.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Crinetics Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crinetics Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crinetics Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
